AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

A series of reports released today by the European Centre for Disease Prevention and Control (ECDC) show sexually transmitted ...

As advertisers pay more for an ever-scarcer supply of ratings points, pharma’s ironclad devotion to TV could finally be in jeopardy ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.